Article ; Online: An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
2023 Volume 16, Issue 3, Page(s) 157–161
Abstract: Introduction: Von Willebrand Factor (VWF) containing concentrates have been used for the treatment of von Willebrand Disease (VWD) for many years. Recently, however, a novel recombinant VWF (rVWF or vonicog alpha, VONVENDI [US], VEYVONDI [Europe]) has ... ...
Abstract | Introduction: Von Willebrand Factor (VWF) containing concentrates have been used for the treatment of von Willebrand Disease (VWD) for many years. Recently, however, a novel recombinant VWF (rVWF or vonicog alpha, VONVENDI [US], VEYVONDI [Europe]) has arrived to the market for the treatment of VWD. Initially, rVWF was approved by the U.S. Food and Drug Administration (FDA) for the on-demand treatment and control of bleeding episodes and for the perioperative management of bleeding for patients with VWD. More recently, however, the FDA has approved rVWF for routine prophylaxis to prevent bleeding episodes for those patients with severe type 3 VWD receiving on-demand therapy. Areas covered: This review will focus on recent phase III trial results from NCT02973087 regarding the use of long-term routine twice weekly prophylaxis with rVWF for the prevention of bleed events in patients with severe type 3 VWD. Expert opinion: A novel rVWF concentrate may have greater hemostatic potential over prior plasma-derived VWF concentrates and is now FDA approved for use in routine prophylaxis for patients with severe type 3 VWD in the United States. This greater hemostatic potential may be due to the presence of ultra-large VWF multimers and a more favorable high-molecular-weight multimer pattern compared to prior pdVWF concentrates. |
---|---|
MeSH term(s) | Humans ; Adult ; von Willebrand Factor/therapeutic use ; von Willebrand Diseases/drug therapy ; von Willebrand Disease, Type 3/drug therapy ; Recombinant Proteins ; Hemorrhage/etiology ; Hemorrhage/prevention & control ; Hemostatics/therapeutic use |
Chemical Substances | von Willebrand Factor ; Recombinant Proteins ; Hemostatics |
Language | English |
Publishing date | 2023-03-02 |
Publishing country | England |
Document type | Review ; Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2516804-6 |
ISSN | 1747-4094 ; 1747-4086 |
ISSN (online) | 1747-4094 |
ISSN | 1747-4086 |
DOI | 10.1080/17474086.2023.2184339 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6943: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.